CURRICULUM VITAE

Christopher L. Amling, M.D., F.A.C.S

PERSONAL

Birth Date: December 23, 1958

Birthplace: Palo Alto, California
Spouse: Barbara L. Amling
Children: Melissa Kathleen
Caroline Marie
Thomas Christopher

Business Address: Division of Urology

Oregon Health & Science University
Center for Health & Healing, CH10U
3303 SW Bond Avenue
Portland, OR 97239

Home Address: 668 McVey Avenue, #75

Lake Oswego, OR 97034

Telephone/Fax: (503) 346-1500/(503) 346-1501

Email Address: amling@ohsu.edu

CURRENT POSITION

Professor and Chief, Division of Urology 3/2009 - present

Oregon Health & Science University, Portland, Oregon

PREVIOUS POSITIONS

Professor and Director, Division of Urology 10/2005 – 2/2009

University of Alabama at Birmingham

Endowed Chair:
Anton J. Bueschen Endowed Chair in Urologic Surgery 6/2006 – 2/2009
and Research, Division of Urology, University of
Alabama at Birmingham

Chairman, Department of Urology 2/2004 – 7/2005

Naval Medical Center, San Diego, California

Residency Program Director, Department of Urology 7/2002 – 7/2005

Naval Medical Center, San Diego, California

ACADEMIC APPOINTMENTS
 Professor, Department of Surgery, Division of Urology 3/2009 – present
Oregon Health & Science University, Portland, Oregon

Professor, Department of Surgery, Division of Urology 10/2005 – 2/2009

University of Alabama at Birmingham

Senior Scientist, Comprehensive Cancer Center 10/2005 – 2/2009

University of Alabama at Birmingham

Assistant Professor of Surgery (Urology) 9/2000-7/2005

Uniformed Services University of the Health Sciences

EDUCATION

Undergraduate: University of Oregon, Eugene, OR 1977-1981

Bachelor of Science, General Science

Medical School: Oregon Health Sciences University, Portland, OR 1981-1985

Doctor of Medicine (Cum Laude)

Internship: Oakland Naval Hospital, Oakland, CA 1985-1986

General Surgery internship

Aerospace Medicine: Naval Flight Surgery Training Program

Naval Aerospace Medical Institute (NAMI)
Pensacola, FL 1987

Residency: Duke University Medical Center, Durham, NC 1990-1992

Junior Resident, Department of Surgery
Chairman: David C. Sabiston, M.D.

Duke University Medical Center, Durham, NC 1992-1996

Resident, Department of Surgery, Division of Urology
Chairman: David F. Paulson, M.D.

Fellowship: Mayo Clinic, Rochester, MN 1996-1997

Department of Urology
Urologic Oncology
Fellowship Director: Horst Zincke, M.D., PhD.

MILITARY

1981 Full scholarship - Navy Health Professions Scholarship Program

1985 Promoted to Lieutenant, U.S. Navy Medical Corps
1985 General Surgery Internship, Oakland Naval Hospital
1986 Staff Physician, Oakland Naval Hospital Emergency Room
1987 Winged U.S. Naval Flight Surgeon, Aerospace Medicine training, Naval Aerospace Medical
Institute, Pensacola, FL (Ranked third in class)
1987 Flight Surgeon, Marine Air Group-24, Kaneohe Bay, HI

2
 1987 Senior Medical Officer and Flight Surgeon, U.S. Marine Corps Medium,
Helicopter Squadron-165, Deployment to Okinawa, Japan. Awarded Naval Service and
Fleet Marine Force Ribbons
1988 Flight Surgeon, VMFA-235 (U.S. Marine Corps fighter/attack squadron), Kaneohe Bay, HI
1989 Promoted to Lieutenant Commander, U.S. Navy Medical Corps
1997 Staff Urologic Oncologist, Department of Urology, Naval Medical Center, San Diego, CA
1997 Promoted to Commander, U.S. Navy Medical Corps
1998 Head, Department of Urology, USNS Mercy Hospital Ship, San Diego,CA
2003 Promoted to Captain, U.S Navy Medical Corps
2005 U.S Navy Retirement

HONORS AND AWARDS

1985 Cum Laude Graduate, Oregon Health Sciences University, School of Medicine
1992 Teaching Resident, Department of Surgery, Duke University Medical Center
1993 Urologic Oncology Award, Division of Urology, Duke University Medical Center
1998 Uro-Oncology Award - Best paper presented at the 46th Annual James C. Kimbrough Urologic
Seminar, Williamsburg, VA
1998 Co-Author, Best Resident Paper Award (Second Place), Kimbrough Urologic Seminar, San
Antonio, TX
1999 Pfizer Scholar in Urology Award, Department of Urology, Naval Medical Center, San Diego, CA
1999 Senior Author, Best Poster of Session, Western Section AUA Meeting, Palm Desert, CA
2000 Senior Author, Best Paper, Round Table Program, Western Section AUA Meeting, Palm Desert,
CA
2000 Navy and Marine Corps Commendation Medial – Meritorious service as a Urologic Oncologist,
Department of Urology, Naval Medical Center, San Diego, CA
2001 Senior Author, Best Resident Paper Award (First Place), Kimbrough Urologic Seminar, San
Diego, CA
2001 Co-Author, Best Subspecialty Paper, San Diego Section of the American College of Surgeons
2002 Uro-Oncology Award – Best paper presented at the 49th Annual James C. Kimbrough Urologic
Seminar, Seattle, WA
2002 Navy and Marine Corps Commendation Medal – Clinical research activity, Clinical Investigation
Department, Naval Medical Center, San Diego, CA
2002 Staff Teaching Award, Department of Urology, Naval Medical Center, San Diego, CA
2002 Senior Author, Best Poster of Session (First Place), Western Section AUA Meeting, Kauai, HI
2003 Senior Author, Best Poster of Session (Third place), Western Section AUA Meeting, Las Vegas,
NV
2003 Co-Author, First Prize, Miley B. Wesson Resident Essay Competition, Western Section AUA
Meeting, Las Vegas, NV
2003 Co-Author, Outstanding Poster Presentation, Society of Urologic Oncology Annual Meeting,
Bethesda, MD
2004 Senior Author, First Prize, Resident Academic Competition, San Diego Urologic Society, San
Diego, CA
2004 First Prize, Best Staff Research Paper, Academic Research Competition, Clinical Investigation
Department, Naval Medical Center, San Diego
2005 Senior Author, Best Resident Paper Award (Third Place), Kimbrough Urologic Seminar,
Honolulu, HI
2005 Meritorious Service Medal – Navy career end award for contributions as clinician, researcher,
mentor and teacher, Department of Urology, Naval Medical Center, San Diego, CA
2007 Co-Author, First Prize, Montague Boyd Essay Contest, Southeastern Section AUA Meeting,
3
 Orlando, FL
2009 AUA Gold Cystoscope Award, AUA Meeting, Chicago, IL

LICENSURE AND CERTIFICATION

Diplomate, American Board of Urology, March 1999

Medical License, State of California, License Number G58152 (inactive)
Medical License, State of Minnesota, License Number 38949 (inactive)
Medical License, State of North Carolina, License Number 94-00011 (inactive)
Medical License, State of Hawaii, License Number 6061(inactive)
Medical License, State of Alabama, License Number 26881
Medical License, State of Oregon, License Number MD29001
Diplomate of the National Board of Medical Examiners
Advanced Trauma Life Support (ATLS) Certification
Basic and Advanced Cardiac Life Support (ACLS) Certification

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

Current:
Fellow, American College of Surgeons
American Urologic Association
Southeastern Section of the American Urologic Association (SESAUA)
Local Arrangement Chairman, Southeastern Section AUA Meeting, San Diego, CA (3/08)
Society of Urologic Oncology
Society of University Urologists (SUU)
Executive Board, Society of University Urologists (SUU)
Society of Urology Chairman and Program Directors (SUCPD)
Society of Government Service Urologists (SGSU)

Past:
Western Section, American Urologic Association (1998-2005)
Alternate District Representative, Executive Board, Western Section AUA (2000-2002)
District Representative, Executive Board, Western Section AUA (2003-2005)
Local Arrangements Chairman, Western Section AUA Meeting, San Diego, CA, 8/2004
Vice-President, Uniformed Services Urology Research Group (2002-2003)
President, Uniformed Services Urology Research Group (2004-2005)
Secretary, San Diego Urologic Society (2001-2003)
Vice President, San Diego Urologic Society (2003-2004)
President, San Diego Urologic Society (2005)

4
NATIONAL COMMITTEES
Residency Review Committee (RRC) for Urology (6/2007 – present)
Program Committee, American Urological Association (5/2006 – present)
Public Media Committee, American Urological Association (5/2006 – present)
American Urologic Association Research Council (5/2004 - present)
Chairman, Fellowship Committee, Society of Urologic Oncology (5/2007 – present)
Secretary, Society of University Urologists (5/2006 – 5/2008)
President-Elect, Society of University Urologists (5/2008 – present)
National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines Panel, Early Detection
(10/2007 – present)
ACGME Advisory Committee on Education Outcome Assessment (6/2007 – present)
Prostate Subcommittee, PLCO Screening Trial (7/2007 – present)

SCIENTIFIC ACTIVITIES

Editorial Boards:
Journal of Urology
Prostate Cancer and Prostatic Diseases
Section Editor – Current Prostate Reports

Journal Reviewer:
Journal of Urology
Urology
Prostate Cancer and Prostatic Diseases
European Urology
Journal of the American Medical Association (JAMA)
American Journal of Surgery
Cancer

VISITING PROFESSORSHIPS

• Mayo Clinic, Rochester, MN – January 10-11, 2002

• Walter Reed Army Medical Center, Washington, DC – March 21, 2002
• National Naval Medical Center, Bethesda, MD – March 22, 2002
• Tripler Army Medical Center, Honolulu, HI – August 18-19, 2003
• Mayo Clinic, Scottsdale, AZ – June 7-8, 2004
• University of Minnesota, Minneapolis, MN – September 22-23, 2004
• University of Kansas, Kansas City, KS – April 5-6, 2007

INVITED NATIONAL AND REGIONAL LECTURES

• “Use of PSA and PSA Isoforms in the Diagnosis of Prostate Cancer” - Society of Urologic Nurses
Association (SUNA) National Meeting, Rochester, MN – May 1997
• “Use of Complimentary Medicine in the Prevention of Prostate Cancer” – West Texas Kidney
Foundation, Texas Tech University Medical Center, Lubbock, TX – September 2000
• State of the Art Lecture: “Prostate Biopsy Strategies”, Kimbrough Urologic Seminar, San Diego,
CA, January 2001.
• “Use of Adjuvant and Neoadjuvant Hormonal Therapy in the Treatment of Advanced Prostate

5
 Cancer” – MEC Regional Symposium, Greensboro, NC – June 12, 2001
• “Treatment of PSA Only Recurrence after Definitive Therapy for Prostate Cancer” – MEC
Regional Symposium, Los Angeles, CA – September 21, 2001
• “Strategies in the Treatment of Advanced Prostate Cancer” – Minnesota Urologic Society
Meeting, Minneapolis, MN – January 11, 2002
• “Evaluation and Treatment of PSA Only Recurrence after Radical Prostatectomy or Radiation
Therapy” – ICPME Regional Symposium, Dallas, TX – February 22, 2002
• “Update on the Use of Hormonal Therapy in the Treatment of Advanced Prostate Cancer” -
Meeting the Challenges in Abdominopelvic Malignancies in the New Mellenium, City of Hope
Cancer Center, Carlsbad, CA - March 16, 2002
• “Strategies in the Management of PSA Recurrence” – Washington DC Urologic Society Meeting,
Washington, DC – March 21, 2002.
• “Multimodal Treatment of Advanced Prostate Cancer” – ICPME Regional Symposium, Houston,
TX – June 21, 2002
• “Evaluation and Treatment of PSA Only Recurrence after Radical Prostatectomy or Radiation
Therapy” – ICPME Regional Symposium, Pasadena, CA – August 9, 2002
• “Advances in the Surgical Treatment of Prostate Cancer” - Radiologic Society of San Diego
Symposium, San Diego, CA - November 2002
• “Update on Prostate Cancer Screening and Biopsy Techniques” – ICPME Regional Symposium,
Seattle, WA – March 21, 2003
• “Incorporating the ACGME Competencies Into a Urology Residency Program” – Annual ACGME
Workshop – Chicago, IL - March 6, 2003
• “Incorporating the ACGME Competencies Into a Urology Residency Program: The Naval
Medical Center San Diego Experience” Society of University Urologists Annual Meeting, AUA
Meeting, Chicago, IL – April 25, 2003
• “Update on Prostate Cancer Screening and Biopsy Techniques” – ICPME Regional Symposium,
Tampa, FL - May 16, 2003
• “Complimentary and Alternative Medicine in Prostate Cancer” – ICPME Regional Symposium,
Tampa, FL - May 16, 2003
• “Complications of Advanced Prostate Cancer” – ICPME Regional Symposium, Tampa, FL - May
16, 2003
• “Neoadjuvant and Adjuvant Use of Hormonal Therapy with Radical Prostatectomy” – Takeda
International Advisory Board Meeting, Los Angeles, CA - June 28, 2003
• “Update on Prostate Cancer Screening, Detection and Biopsy Techniques” – ICPME Regional
Symposium, Kansas City, Kansas - July 18, 2003
• “Incorporating the ACGME Competencies Into a Urology Residency Program: The Naval
Medical Center San Diego Experience” Society of University Urologist Chairman and Program
Directors Meeting, Chicago, IL – November 17, 2003
• “Treatment of Advanced Prostate Cancer – A United States Perspective” – Prostate Cancer Global
Opinion Leaders Workshop, Paris, France - January 29, 2004
• “Update on Urologic Imaging” and “Update on Prostate Cancer Screening and Biopsy
Techniques” – Loma Linda University and USC “Controversies in Urology” Meeting, Mammoth,
CA – February 21, 2004
• “Management Strategies for PSA Recurrence after Radical Prostatectomy or Radiation Therapy”,
University of California San Francisco (UCSF) Grand Rounds – April 14, 2004
• “Web-based Competency Evaluation System”, Society of University Urologists Annual Meeting,
San Francisco, CA – May 7, 2004.
• “Current Controversies in Prostate Cancer”, Pellar Annual Endowed Lecture, Mayo Clinic,
Scottsdale, AZ – June 7, 2004.
• “Complications of Advanced Prostate Cancer Treatment” - ICPME Regional Symposium, San
Francisco, CA – June 18, 2004.

6
• “Use of Adjuvant and Neoadjuvant Hormonal Therapy in Locally Advanced Prostate Cancer”,
Asian Prostate Cancer Lecture Series: Bangkok, Thailand, Manilla, Philippines and Taipei,
Taiwan – July 10-18, 2004.
• “What’s New and in the News: Early Stage Treatment for Prostate Cancer 2004” – Perspectives
in Men’s Health Regional Program, San Francisco, CA – July 23, 2004.
• “Complications of Advanced Prostate Cancer Treatment” - ICPME Regional Symposium,
Washington, DC – July 30, 2004.
• “Update on Prostate Cancer Screening and Biopsy Techniques” and “Optimal Integration of
Chemotherapy and Hormonal Therapy for Biochemical Recurrence”– ICPME Regional
Symposium, Dearborn, MI – August 13, 2004.
• “Diagnosis and Treatment of Penile and Urethral Cancer” – Western Section AUA Meeting PREP-
C Course, San Diego, CA – August 23, 2004.
• “Strategies for Management of PSA Recurrence after Radical Prostatectomy or Radiation
Therapy” University of Minnesota Medical Center, Minneapolis, MN – September 22, 2004
• “Incorporating the ACGME Competencies Into a Residency Program: The Naval Medical Center
San Diego Urology Experience” University of Minnesota Medical Center, Minneapolis, MN –
September 22, 2004
• “Update on the Diagnosis and Treatment of Penile and Urethral Cancer” – University of
Mississippi, Jackson, MS – November, 2004.
• “Optimal Integration of Chemotherapy and Hormonal Therapy for Biochemical Recurrence”–
ICPME Regional Symposium, Los Angeles, CA – November 5, 2004.
• “Strategies for Management of PSA Recurrence after Radical Prostatectomy or Radiation
Therapy” - Shands Hospital, University of Florida, Gainesville, FL – January 12, 2005.
• “Residency Education in Military Urology Training Programs – Incorporation of the ACGME
Competencies and Duty Hour Restrictions” – Kimbrough Urologic Seminar, Honolulu, HI –
January 17, 2005.
• “Who is Most Likely to Progress?” – Issues and Controversies in Prostate Care 2005, Jamaica,
W.I. - March 11, 2005.
• “Obesity and Prostate Cancer” – 1st Annual DukeProstateCenter (DPC) Symposium: Carolina
Prostate Cancer Clinical Trials and Care Update - 2005, Duke University Medical Center,
Durham, NC – April 9, 2005.
• “New Concepts in Prostate Cancer Screening and Prevention”, Recent Advances in the
Management of Prostate Cancer, Los Angeles, CA – April 22, 2005.
• “Evidence­Based Use of Neoadjuvant and Adjuvant Hormonal Therapy”  ­  AUA Postgraduate 
Course, San Antonio, TX ­ May 23, 2005.
• “Obesity and Prostate Cancer” – UAB Comprehensive Cancer Center Retreat and Research 
Competition, Birmingham, AL – August 25, 2005.
• “Obesity and Prostate Cancer” – 2005 Urology Symposium, Santa Barbara, CA – October 21­23, 
2005.
• “Use of Neoadjuvant and Adjuvant Hormonal Therapy with Radical Prostatectomy and 
Radiotherapy” – 2005 Urology Symposium, Santa Barbara, CA – October 21­23, 2005.
• “Management of PSA Recurrences After Radical Prostatectomy Case Presentations” – 2005
Urology Symposium, Santa Barbara, CA – October 21-23, 2005.
• “Overview and Update on Penile and Urethral Cancer” – 2005 Urology Symposium, Santa
Barbara, CA – October 21-23, 2005.
• “Clinical Applications of PSA Kinetics” – Sixth Annual Society of Urologic Oncology Meeting,
Bethesda, MD – December 2-3, 2005.

7
• “Point-Counterpoint: Are the Technological Advances in the Surgical Management of Prostate
Cancer Truly Advances?” – 53rd Kimbrough Urologic Seminar, Savannah, GA – January 15-20,
2006.
• “Clinical Applications of PSA Kinetics in Prostate Cancer” – University of Kentucky, Lexington,
KY – Febraury 15, 2006.
• “PSA Kinetics” – TAP University, Las Vegas, NV – February 22, 2006.
• “Clinical Applications of PSA Kinetics” – University Associates of North Texas, Dallas, TX –
April 11, 2006.
• “Obesity and Prostate Cancer” – Advances in Uro-Oncology: Eine Festschrift for Horst Zincke,
MD, PhD, Rochester, MN – April 29, 2006.
• “Hormonal Therapy and Prostate Cancer: New Uses for an Old Treatment” – AUA Postgraduate
Course, Atlanta, GA – May 24, 2006.
• “Treatments and Risk Factors for Prostate Cancer” – Conference on Cancer Survivorship Issues
in the African-American Community, Birmingham, AL – June 6, 2006.
• “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate
Cancer Review: Redefining Patient Care”, Tampa, FL – June 16, 2006.
• “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer
Review: Redefining Patient Care”, Tampa, FL – June 16, 2006.
• “Clinical Applications of PSA Kinetics in Prostate Cancer” – Urology Seminar, Destin, FL – July
13-16, 2006.
• “Upate on Robotic Prostatectomy for Prostate Cancer” – University of Alabama at Birmingham,
Department of Surgery Grand Rounds, Birmingham, AL – August 17, 2006.
• “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate
Cancer Review: Redefining Patient Care, Washington, DC – September 15, 2006.
• Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer
Review: Redefining Patient Care, Washington, DC – September 15, 2006.
• “Robotics, Laparoscopic and Open Prostatectomy Options” – Annual Multidisciplinary Approach
to the Management of Prostate and GU Cancer Conference, Dallas, TX – September 29-October,
1 2006.
• “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate
Cancer Review: Redefining Patient Care”, Chicago, IL – October 27, 2006.
• “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer
Review: Redefining Patient Care”, Chicago, IL – October 27, 2006.
• “Robotic Prostatectomy” – 4th Annual Georgia Urological Association Spring Meeting & Urology
Resident Research Expo, Savannah, GA – February 16-18, 2007.
• “Hormonal Therapy and Prostate Cancer: Evidence Based Approaches in 2007.” – AUA
Postgraduate Course, Anaheim, CA - May 2007.
• “Chemoprevention / Risk Factors for Prostate Cancer” – The Minnesota Urological Society
Annual Spring Seminar, St Paul, MN – May 11-12, 2007.
• “New and Emerging Technologies in Prostate Cancer Prevention, Diagnosis and Treatment” – 
Prostate Cancer Summit 2007 Call to Action, Birmingham, AL – June 2007.
• “Point-Counterpoint: Is Robotic Prostatectomy Really Better than Open Prostatectomy?” – 
Urology Seminar, Destin, FL – August 9­12, 2007.
• “The Role of Radical Prostatectomy in High Risk Prostate Cancer” – Urology Seminar, Destin, 
FL – August 9­12, 2007.
• “Core Competencies” University of Alabama School of Medicine Surgery Grand Rounds, 
Birmingham, AL – August 23, 2007.
• “The Role of Obesity in Urology” – AUA Northeastern Section Meeting, Rochester, NY –
September 6-7, 2007.
8
• “Current Challenges in Urology Residency Training” – AUA Northeastern Section Meeting,
Rochester, NY – September 6-7, 2007.
• “Hormonal Therapy and Prostate Cancer: Evidence Based Approaches in 2008.” – AUA
Postgraduate Course, Orlando, FL - May 2008.

RESEARCH SUPPORT

Current:
• TNG-CL005, Tengion, Inc. – A Multicenter Study to Obtain Full Thickness Bladder Tissue
Specimens from Subjects Undergoing Cystectomy
Role: PI 1/1/2007-7/31/2009
$25,494
Purpose: To obtain full-thickness bladder wall tissue at the time of cystectomy for use in
development of bladder tissue constructs
• UAHSF Endowment Grant – UAB Men’s Contienence Center
Role: CI 3/1/2008-2/28/2010
$164,680
Purpose: To follow a chort of men undergoing radical prostatectomy and collect follow-
up data on health status and quality-of-life for one year after surgery
• NCI N01-CN-75022 – Prostate, Lung, Colo-rectal and Ovarian (PLCO) Cancer Screening Trial
Role: CI 9/1/2007-9/29/2009
$9,372
Purpose: Evaluate effectiveness of screening for prostate cancer; includes a
biorepository (blood samples) and accompanying data collection on risk factors
• VA01162 Cooperative Studies Program – Chemotherapy after Prostatectomy for High Risk
Prostate Cancer: A Phase III Randomized Study
Role: CI 1/1/2008-12/31/2008
Purpose: Investigate effectiveness of adjuvant chemotherapy to decrease recurrence rate
after radical prostatectomy for high risk prostate cancer patients
• 2008 GSR-DG - Geriatrics Education for Specialty Residents Dissemination Grant
Role: CI 7/1/2008-6/30/2009
$25,000
Pupose: Improvement of geriatric education among urology residents by development and
implementation of curricula and expansion of research focusing on the geriatric
population
• UAB X030820007 – Protocol for Obtaining Solid Tissues, Fluids, and Information for
Genitourinary Cancer Research
Role: PI 1/1/2006-12/31/2009
Pupose: Develop tissue and body fluid repository for use in urologic cancer research
Pending:
• UAB 0516 (NCI -University of Wisconsin Consortium) – Phase II Study of Isoflavone G-2535
(Genistein) in Patients with Baldder Cancer
Role: CI
• UAB 0810 (NCI -University of Wisconsin Consortium) – Phase II Randomized Placebo-
Controlled Trial of Polyphenono-E to Evaluate Baldder Tissue Levels of EGCG
Role: CI
Past:
• DOD Center for Prostate Disease Research Grant . – Military Multicenter Prostate Cancer
Database Investigating Patterns of Care, Outcomes and Prognostic Factors
Role: Site (NMCSD) PI

9
 • DOD-Armed Forces Institute of Pathology Grant – A Uniformed Services Comprehensive
Database and Tissue Repository for the Study of Epidemiology, Detection, Natural History and
New Management Strategies for Prostate Cancer
Role: Site (NMCSD) PI
• Astra-Zeneca Pharmaceuticals – A Randomized Double-Blind Comparitive Trial of Bicalutamide
(Casodex) 150 mg Monotherapy versus Placebo in Patients with a Rising PSA after Radical
Prostatectomy
Role: Site (NMCSD) PI
• Sidney Kimmel Cancer Center (SKCC) Grant – Tissue Collection for Investigation of Vascular
Markers in Urologic Malignancies
Role: Site (NMCSD) PI
• Ortho-McNeil Pharmaceuticals – A Multicenter, Double-Blind Study to Compare the Safety and
Efficacy of Levofloxacin to Ciprofloxacin in the Treatment of Chronic Prostatitis
Role: Site (NMCSD) PI
• American Medical Systems – Evaluation of the Safety and Tolerability of Transurethral
Dehydrated Alcohol Injection for the Treatment of Benign Prostatic Hyperplasia
Role: Site (NMCSD) PI

PEER-REVIEWED PUBLICATIONS

1. Amling, C.L., Thrasher, J.B., Frazier, H.A., Dodge, R.K., Robertson, J.E. and Paulson D.F.:
Radical cystectomy for stages Ta. Tis and T1 transitional cell carcinoma of the bladder. J. Urol.,
151:31-36, 1994.
2. Amling, C.L., O’Hara, S.M., Wiener, J.S., Schaeffer, C.S. and King, L.R.: Renal ultrasound
changes following pyeloplasty in children with UPJ obstruction: Long term outcome in 47 renal
units. J.Urol., 156:2020-2024, 1996.
3. Lo, J., Kerns, B.J., Amling, C.L., Robertson, C.N. and Layfield, L.J.: Correlation of DNA ploidy
and histologic diagnosis for prostate core needle biopsies: Is DNA ploidy more sensitive than
histology for the diagnosis of carcinoma in small specimens? J Surg Oncol 63(1):41-45, 1996.
4. Amling, C.L., Blute, M.L., Lerner, S.E., Bergstralh, E.J., Bostwick, D.G. and Zincke, H.:
Influence of PSA testing on the spectrum of patients with prostate cancer undergoing radical
prostatectomy at a large referral practice. Mayo Clin Proc 73:401-406, 1998.
5. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J.M., Martin, S.K. and Zincke, H.:
Preoperative androgen deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol
15(4):222-229, 1997.
6. Amling, C.L., Leibovich, B.C., Lerner, S.E., Bergstralh, E.J., Blute, M.L., Myers, R.P. and 
Zincke, H.:  Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. 
Semin Urol Oncol 15(4):215­221, 1997.
7. Blute, M.L., Bostwick D.G., Bergstralh, E.J., Martin, S. K., Amling, C.L. and Zincke, H.:
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on
outcome after radical prostatectomy. Urology 50:733-739, 1997.
8. Amling, C.L., Lerner, S.E., Martin, S.K., Slezak, J.M., Blute, M.L. and Zincke, H.: DNA ploidy
and serum PSA levels predict outome following salvage prostatectomy for radiation refractory
prostate cancer. J Urol 161:857-863, 1999.
9. Lerner, S.E., Amling, C.L., Kaynan, A.M., Blute, M.L. and Zincke, H.: The role of salvage
surgery in radio-recurrent/resistant carcinoma of the prostate. AUA Update, Vol 28 (Lesson 8),
1999.
10. Borboroglu, P.G., Roberts, J.L. and Amling, C.L.: Late pelvic recurrence of nonseminomatous
testicular carcinoma after negative retroperitoneal lymph node dissection. Urology 54:923-924,
1999.
10
11. Borboroglu, P.G., Comer, S.W., Riffenburgh, R.H. and Amling, C.L.: Extensive repeat transrectal
ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol
163:158-162, 2000.
12. Borboroglu, P.G., Sands, J.P., Roberts, J.L. and Amling, C.L.: Risk factors for vesicourethral
anastomotic stricturs after radical prostatectomy. Urology 56:96-100, 2000.
13. Amling, C.L., Seay, T,M., Blute, M.L., Bergstralh, E.J. and Zincke, H.: Long-term hazard of
progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of
biochemical failure after five years. J Urol 164:101-105, 2000.
14. Blute, M.L., Amling, C.L., Bryant, S.C. and Zincke, H.: Mangement and extended outcome of
patients with synchronous bilateral solid renal neoplasms in the absence of Von Hippel-Lindau
disease. Mayo Clin Proc 75(10):1020-1026, 2000.
15. Borboroglu, P.G. and Amling, C.L.: Correlation of prostate sextant biopsy location to sites of
positive surgical margins in radical prostatectomy specimens. Eur Urol 39:638-644, 2001.
16. Tarman, G.J., Kane, C.J., Moul, J.W., Thrasher, J.B., Foley, J., Riffenburgh, R.H. and Amling,
C.L.: Impact of socioeconomic status and race on clinical parameters of patients undergoing
radical prostatectomy in an equal access health care system. Urology 56:1016-1020, 2000.
17. Ward, J.F., Sands, J.P., Nowacki, M.R. and Amling, C.L.: Malignant cells in prostate washings
predicts biochemical progression after radical prostatectomy. J Urol 165:469-473, 2001.
18. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J. and Zincke, H.: Defining biochemical
progression after radical prostatectomy: What is the most appropriate PSA cut-point? J Urol
165:1146-51, 2001.
19. Gray, C.L., Powell, C.R. and Amling, C.L.: Outcomes for surgical management of scrotal pain in
patients with identifiable intrascrotal lesions. Eur Urol 39:455-459, 2001.
20. Borboroglu, P.G., Sur, R.L., Roberts, J.L. and Amling, C.L.: Repeat biopsy strategy in patients
with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial
prostate biopsy. J Urol 166:866-870, 2001.
21. Amling, C.L., Kane, C.J., Ward, J.F., Roberts, J.L., Lance, R.S., Friedrichs, P.A. and Moul, J.W.:
Relationship between obesity and race in predicting adverse pathologic variables in patients
undergoing radical prostatectomy. Urology 58:723-728, 2001.
22. Borboroglu. P.G., Amling, C.L., Bishoff, J.T., Monga, M., Schenkman, N.S. and Kane, C.J.:
Ureteral stenting after ureteroscopy for distal ureteral calculi: Multi-institutional prospective
randomized study assessing pain, outcomes and complications. J Urol 166:1651-1657, 2001.
23. Johnstone, P.A.S., McFarland, J.T., Riffenburgh, R.H. and Amling, C.L.: Efficacy of digital rectal
examination after radiotherapy for prostate cancer. J Urol 166:1684-1687, 2001.
24. Amling, C.L.: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer
25(4):217-280, 2001.
25. Gray, C.L., Amling, C.L., Polston, G.R., Powell, C.R. and Kane, C.J.: Intraoperative cell salvage
in radical retropubic prostatectomy. Urology 58:740-745, 2001.
26. Moul, J.W., Wu, H., Sun, L., Mcleod, D.G., Amling, C.L., Lance, R., Kusuda, L., Donahue, T.,
Foley, J., Chung, A., Sexton, W., Soderdahl, D.: Epidemiology of radical prostatectomy for
localized prostate cancer in the era of prostate-specific antigen (PSA): An overview of the DOD
Center for Prostate Disease Research (CPDR) National Database. Surgery 132:213-9, 2002.
27. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr., Terris MK, and Aronson WJ. Race as
an outcome predictor following radical prostatectomy: results from the Shared Equal Access
Regional Cancer Hospital (SEARCH) Database. Urol 60: 670-674, 2002.
28. Johnstone PAS, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R,
Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL: The effect
of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive
radiation therapy in an equal-access health care system: Radiation oncology report of the DOD
Center for Prostate Disease Research. Radiology 225:420-6, 2002.
29. Gray-Sears, C.L., Ward, J.F., Sears, S.T., Puckett, M.L. Kane, C.J. and Amling, C.L.: Prospective

11
 comparison of CT and IVP in the initial evaluation of asymptomatic microhematuria. J Urol
168:2457-60, 2002.
30. Desai A., Wu H., Sun L, Sesterhenn I.A., Mostofi F.K., McLeod D., Amling C., Kusuda L., 
Lance R., Herring J., Foley J., Baldwin D., Bishoff JT., Soderdahl D., Moul J.W. Complete 
embedding and close step­sectioning of radical prostatectomy specimens both increase detection 
of extra­prostatic extension, and correlate with increased disease­free survival by stage of prostate 
cancer patients. Prostate Cancer Prostatic Dis. 5:212­18, 2002.
31. Johnstone, P.A.S., Booth, R., Riffenburgh, R.H., Amling, C.L., Kane, C.J. and Moul, J.W.:
Initiation of salvage therapy for prostate cancer. Prostatic Cancer Prostatic Dis 5:136-43, 2002.
32. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Amling CL, Dorey F, and Aronson WJ.
Comparison of preoperative PSA density and PSA for predicting recurrence after radical
prostatectomy: Results from the SEARCH database. J Urol 169:969-73, 2003.
33. Johnstone PAS, Bloom TL, Niemtzow RC, Crain DS, Riffenburgh RH, Amling CL: A 
prospecitive, randomized pilot trial of acupuncture of the kidney­bladder distinct meridian for 
lower urinary tract symptoms. J Urol 169:1037­9, 2003.
34. Bloom TL, Gray­Sears CL, Williams TR, Linfesty RL, Amling CL: Multilocular cystic renal cell 
carcinoma with osseous metaplasia in a 25­year old woman. Urology 61:462, 2003.
35. Ward JW, Amling CL, McKusick MA: The use of percutaneous transcatheter embolization in
urology. AUA Update, Vol 22 (Lesson 39 ), 2003.
36. Johnstone, P.A.S., Riffenburgh R.H., Kane, C.J., Sun, L., Moul, J.W., McLeod, D.G., Martin,
D.D., Kusuda, L., Lance, R.L., Donahue, T., Foley, J., Soderdahl, D., Amling, C.L.: The effect of
age on biochemical disease-free outcome in patients with T1-3 prostate cancer treated with
definitive radiation therapy in an equal-access health care system: A radiation oncology report of
the DOD Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys 15;55:964-9, 2003.
37. Kane, C.J., Amling, C.L., Johnstone, P.A.S., Pak, N., Lance, R.S., Thrasher, J.B., Foley, J.P.,
Riffenburgh, R. and Moul, J.W.: Limited value of bone scintigraphy and computed tomography in
assessing biochemical failure after radical prostatectomy. Urology 61:607-11, 2003.
38. Riffenburgh RH, Amling CL: Use of early PSA velocity to predict eventual abnormal values in
men at risk for prostate cancer. Prostate Cancer Prostatic Dis. 6:39-44, 2003.
39. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Dorey F, and Terris MK. Time 
trends in biochemical recurrence following radical prostatectomy: results of the SEARCH 
database. Urology 61:736­41, 2003.
40. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Terris
MK: Comparison of percent of total prostate needle biopsy tissue with cancer to percent of cores
with cancer for predicting PSA recurrence following radical prostatectomy: results from the
SEARCH database. Urology 61:742-7, 2003.
41. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W,
Kusuda L, Chung A, Soderdahl D, Donahue T: Pretreatment total testosterone level predicts
pathologic stage in patients with localized prostate cancer treated with radical prostatectomy. J
Urol 169:1670-5, 2003.
42. Freedland SJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, Amling CL: Improved 
clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 
prostate cancer: results from the SEARCH database. J Urol 169:2129, 2003.
43. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent 
of prostate needle biopsy cores with cancer is a significant independent predictor of PSA 

12
 recurrence following radical prostatectomy: Results from the SEARCH Database. J Urol 
169:2136, 2003.
44. Freedland SJ, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. 
Should a positive surgical margin following radical prostatectomy be pathological stage T2 or 
T3? Results from the SEARCH Database.  J Urol 169:2142, 2003.
45. Crain DS, Roberts JL, Amling CL: Practice patterns in vasectomy reversal surgery: A 
questionnaire study among practicing urologists. J Urol 171:311-5, 2004
46. Crain DS, Amling CL Kane CJ: Palliative TURP for bladder outlet obstruction in patients with 
locally advanced prostate cancer. J Urol 171:668­71, 2004.
47. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW,
DonahueTF, Foley JP, Chung AK, McLeod DG: Pathologic variables and recurrence rates as
related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin
Onc 22:439-45, 2004
48. Altamar HO, Middleton GW, Capozza TA, Auge BK, Amling CL: Profound anemia from duodenal
invasion of metastatic testicular seminoma. J Urol 171:344-5, 2004.
49. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK: Impact of
obesity on biochemical control following radical prostatectomy for clinically localized prostate
cancer. J Clin Onc 22:446-53, 2004.
50. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, 
Kusuda L, Chung A, Soderdahl D, Jackman S, Moul JW: Temporarily deferred therapy (watchful 
waiting) for men younger than 70 years and with low­risk localized prostate cancer in the 
prostate­specific antigen era. J Clin Oncol 21(21):4001­8, 2003.
51. Freedland SJ, Amling CL, Terris MK, Presti JC Jr, Aronson WJ, Elashoff D, and Kane CJ. Is there
a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4,
5, and 6? Results from the SEARCH Database. Prostate Cancer Prostatic Dis. 2003;6(3):261-
265.
52. Moul J, Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton
W, Soderdahl D, Wu H. A retrospective review on 542 cases in the past decade on associations
between bone metastasis and PSA level, bone pain, and race in prostate cancer patients. Oncology
17(4 Suppl):47-78, 2003
53. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC: The percentage
of prostate needle biopsy cores with cancer from the more involved side of the biopsy as a
predictor of PSA recurrence following radical prostatectomy. Cancer 98(11):2344-50, 2003.
54. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung
A, Soderdahl D, Donahue T. Factors associated with blood loss during radical prostatectomy for
localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the department
of defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol Oncol.
2003; 21(6):447-55.
55. Freedland SJ, Presti JC Jr., Kane CJ, Aronson WJ, Terris MK, Dorey F, and Amling CL. Do
younger men have better biochemical outcomes following radical prostatectomy? Urology 63:518-
22, 2004.
56. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O’Reilly K,
Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific
antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141-1147, 2004
57. Wu H, Sun L, Moul JW, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T Foley J, Chung
A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of
localized prostate cancer. J Urol 171:1111-1116, 2004.

13
58. Sur RL, Borboroglu PG, Roberts JL, Amling, CL. A prospective randomized comparison of
extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and
morbidity. Prostate Cancer Prostatic Dis (Epub ahead of print) 2004.
59. Freedland SJ, Aronson WJ, Presti JC Jr. , Amling CL, Terris MK, Trock B, Kane CJ.  Predictors 
of PSA progression among men with seminal vesicle invasion at the time of radical 
prostatectomy.  Cancer 100:1633­8, 2004.
60. Crum NF, Spencer CR, Amling CL: Prostate cancer among human immunodeficiency virus 
(HIV) –infected men. Cancer 101:294­9, 2004.
61. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL Presti JC, Dorey F, Aronson WJ: Pre­
operative model for predicting PSA recurrence after radical prostatectomy using percent of 
biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. J Urol 171: 2215, 2004.
62. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, Amling CL. 
Biochemical outcome following radical prostatectomy among men with normal pre­operative 
serum PSA values.  Cancer 101:748­53, 2004.
63. Crain DS, Spencer CR, Favata MA, Amling CL: Transureteral iced saline to obtain renal
hypothermia: Potential for application in laparoscopic partial nephrectomy. JSLS 8:217-222, 2004.
64. Freedland SJ, Terris MK, Presti JC Jr. , Amling CL, Kane CJ, Trock B, and Aronson WJ.  Obesity 
and biochemical outcome following radical prostatectomy for pathologically organ­confined 
disease with negative surgical margins.  J. Urol 172:520­4, 2004.
65. Amling CL: Biochemical failure: role for early hormonal therapy. BJU Int 94 Suppl 3:9-10, 2004.
66. Amling CL: Advanced prostate cancer treatment guidelines: a United States perspective. BJU Int
94 Suppl 3:7-8, 2004
67. Amling CL: The association between obesity and the progression of prostate and renal cell 
carcinoma. Urol Oncol 22(6):478­84, 2004.
68. Amling, CL: Case studies in prostate cancer. BJU Int 94 Suppl 3:18-9, 2004.
69. Langenstroer P, Poulton T, Kramer B, Cutting B, Amling CL, Lance RS, Thrasher JB. Multi-
institutional evaluation of depo-provera for the treatment of hot flashes associated with androgen
ablation for prostate cancer. J Urol 174: 642-645, 2005.
70. Gaylis FD, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ: Prostate cancer in men using
testosterone supplementation. J Urol 174: 534-538, 2005.
71. Amling CL: Relationship between obesity and prostate cancer. Curr Opin Urol 15(3): 167-171,
2005.
72. Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R, Thrasher JB: Parenteral
medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot
flashes in men with advanced prostate cancer. J Urol 174: 642-645, 2005.
73. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR: A review of hypogonadism and erectile
dysfunction among HIV-infected men during the pre- and post-HAART eras: Diagnosis,
pathogenesis, and management. AIDS Patient Care STDS 19: 655-71, 2005.
74. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ:
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after
radical prostatectomy: a search database study. J Clin Oncol: 23: 7546-54, 2005.
75. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK;
Shared Equal Access Regional Cancer Hospital Database Study Group: Radical differences in
prognostic value of adult height for biochemical progression following radical prostatectomy. Clin
Cancer Res 11: 7735-42, 2005.
14
76. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK: Obesity,
serum prostate specific antigen and prostate size: Implications for prostate cancer detection. J
Urol 175: 500-4, 2006.
77. Freeland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK, SEARCH Database
Study Group: Delay of radical prostatectomy and risk of biochemical progression in men with low
risk prostate cancer. J Urol 175: 1298-302, 2006.
78. Amling CL: Biochemical recurrence after localized treatment. Urol Clin North AM 33: 147-59,
2006.
79. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr, Mangold
LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ: Clinical and pathologic outcome after
radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Cancer 107: 1265-72, 2006.
80. Amling CL: Prostate-specific antigen and detection of prostate cancer: What have we learned and
what should we recommend for screening? Curr Treat Options Oncol 7: 337-45, 2006.
81. Amling CL: Dilemmas in management of the small renal mass. Curr Opin Urol 16: 315-6, 2006.
82. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson
WJ, Kane CJ, Carroll PR: Multiinstitutional validation of the UCSF cancer of the prostate risk
assessment for prediction of recurrence after radical prostatectomy. Cancer 107: 2384-91, 2006.
83. Morey AF, Evans LA, McDonough RC, Park AM, Sexton WJ, Basler JW, Santucci RA, Amling
CL, O’Reilly KJ: Evaluation of mechanical bowel preparation methods in urinary diversion
surgery. Can J Urol 13: 3250-4, 2006.
84. Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ: Is
biopsy Gleason score independently associated with biochemical progression following radical
prostatectomy after adjusting for pathological Gleason score? J Urol 176: 2453-8, 2006.
85. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Fredland SJ, SEARCH Database
study group: Changing nature of high risk patients undergoing radical prostatectomy. J Urol 177:
113-7, 2007.
86. Crum-Cianflone NJ, Bavaron M, Hale B, Amling CL, Truett A, Brandt C, Pope B, Furtek K,
Medina S, Wallace MR: Erectile dysfunction and hypogonadism among men with HIV. AIDS
Patient Care STDS 21: 9-19, 2007.
87. Plante MK, Marks LS, Anderson R, Amling CL, Rukstalis D, Badlani G, Getlin L, Vang E: Phase
I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic
benign prostatic hyperplasia. J Urol 177: 1030-5, 2007.
88. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr, SEARCH Database
Study Group: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and
clinical implications. Urology 69: 495-9, 2007.
89. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL,
Hammontree LN, Kolettis PN: Computerized tomographic angiography for renal donor evaluation
leads to a higher exclusion rate. J Urol 177: 1826-9, 2007.
90. King CR, Freedland SJ, Terri MK, Aronson WJ, Kane CJ, Amling CL, Presti JC Jr: Optimal
timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to
predict relapse after prostatectomy: a report from SEARCH. Urology 69: 732-7, 2007.
91. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr: Impact of
obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after
prostatectomy: A report from the SEARCH database. Urology 69: 921-6, 2007.
92. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr,
Mangold LA, Freedland SJ: Do racial differences in prostate size explain higher serum prostate-
specific antigen concentrations among black men? Urology 69: 1138-42, 2007.
93. Sajadi KP, Terris MK, Hamilton RK, Cullen J, Amling CL, Kane CJ, Presti JC Jr, Aronson WJ,
Freedland SJ: Body mass index, prostate weight and transrectal ultrasound prostate volume
accuracy. J Urol 178: 990-5, 2007.
94. Scales CD Jr., Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, for the
SEARCH Database Study Group: Predicting unilateral prostate cancer based on biopsy features:
15
 Implications for focal ablative therapy-Results from the SEARCH Database. J Urol 178: 1249-
52, 2007.
95. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland
SJ; SEARCH Database Study Group: Risk stratification of men with Gleason score 7 to 10
tumors by primary and secondary Gleason score: Results from the SEARCH Database. Urology
70(2): 277-82, 2007.
96. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriquez C, Wang Y, Terri MK, Aronson
WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ: Obesity-related plasma
hemodilution and PSA concentration among men with prostate cancer. JAMA 298 (19): 2275-80,
2007.
97. Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Race,
biochemical disease recurrence, and prostate-specific antigen doubling time after radical
prostatectomy: Results from the SEARCH Database. Cancer 110(10): 2153-4, 2007.
98. Buschemeyer WJ 3rd, Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL,
Freedland SJ: Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen
era? Results from the SEARCH Database. J Urol 179: 124-9, 2008.
99. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ,
Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: The effect of race/ethnicity on the
accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer.
Urology 71(1):151-5, 2008.
100. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland
SJ; SEARCH Database Study Group: Small transrectal ultrasound volume predicts clinically
significant Gleason score upgrading after radical prostatectomy: Results from the SEARCH
database. J Urol 179(2): 523-7, 2008.
101. Sengupta S, Amling C, D’Amico AV, Blute ML: Prostate specific antigen kinetics in the
management of prostate cancer. J Urol 179(3):821-6, 2008.
102. Strang AM, Lockhart ME, Amling CL, Kolettis PN, Burns JR: Living renal donor allograft
lithiasis: A review of stone related morbidity in donors and recipients. J Urol 179(3):832-6, 2008.
103. Colli JL, Amling CL: Exploring causes for declining prostate cancer mortality rates in the United
States. Urol Oncol. 2008 Jan 11. [Epub ahead of print]
104. Colli JL, Amling CL: Prostate cancer mortality rates compared to urologist population densities
and prostate-specific antigen screening levels on a state-by-state basis in the United States of
America. Prostate Cancer Prostatic Dis. 2008 Feb 12. [Epub ahead of print]
105. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ,
Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: Small transrectal ultrasound volume
predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the
SEARCH database. J Urol. 2008 179(2):523-7.
106. Colli JL, Amling CL: High cholesterol levels are associated with reduced prostate cancer mortality
rates during periods of high but not low statin use in the United States. Urol Oncol. 2008 Feb 1.
[Epub ahead of print]
107. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K,
Hernandez J, Chung A, Soderdahl D: Early versus delayed hormonal therapy for prostate specific
antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2008, 179(5
Suppl):S53-9.
108. Cox J, Amling CL: Current decision-making in prostate cancer therapy. Curr Opin Urol. 2008,
18(3):275-8.
109. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ:
Limitations of prostate specific antigen doubling time following biochemical recurrence after

16
 radical prostatectomy: results from the SEARCH database. J Urol. 2008;179(5):1785-9;
discussion 1789-90. Epub 2008 Mar 17.
110. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ,
Freedland SJ; SEARCH Database Study Group: Risk stratification for biochemical recurrence in
men with positive surgical margins or extracapsular disease after radical prostatectomy: results
from the SEARCH database. J Urol. 2008;179(5):1791-6; discussion 1796. Epub 2008 Mar 17.
111. Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, Kane CJ: Impact of
nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH
database. Prostate Cancer Prostatic Dis. 2008 Jul 15. Epub ahead of print.
112. Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ:
Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-
based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital
and Duke Prostate Cancer databases. Brit J Urol Internat 2008 Sept; 102(8):969-74, Epub 2008
August 7.
113. SEARCH Database Study Group, Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling
CL, Kane CJ, Freedland SJ: Obesity and positive surgical margins by anatomic location after
radical prostatectomy: results from the Shared Equal Access Recional Cancer Hospital database.
Brit J Urol Internat 2008 Sep; 102(8):964-8. Epub 2008 July 7.
114. Colli JL, Busby JE, Amling CL: Renal cell carcinoma rates compared with health status and
behavior in the United States. Urology 2009 Feb; 73(2):431-6. Epub 2008 August 13.
115. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ; SEARCH
Database Study Group. The association between prostate size and Gleason score upgrading
depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional
Cancer Hospital Database. Brit J. Urol Internat 2008 Nov; 102(9):1074-9. Epub 2008 Sep 3.
116. Teeter AE, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ,
SEARCH Database Group: What are the factors associated with short prostate specific antigen
doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol
2008 Nov; 180(5):1980-4; discussion 1985. Epub 2008 Sep 17.
117. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA: Structural heterogeneity and protein
composition of exosome-like vesicles (prostasomes) in human serum. Prostate. 2009 Feb 1;
69(2):159-67.
118. Schroeck FR, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Do
nomograms predict aggressive recurrence after radical prostatectomy more accurately than
biochemical recurrence alone? Brit J Urol Internat 2009 Mar; 103(5):603-8. Epub 2008 Nov 18.
119. Shah SE, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Terris
MK: Exposure to Agent Orange is a significant predictor of prostate-specific antigen
(PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. Brit J
Urol Internat 2009 Mar 4. Epub ahead of print.
120. Lloyd JC, Banez LL, Aronson WJ, Terris MD, Presti JC Jr., Amling CL, Kane CJ,
Freedland SJ. Preoperative predictors of blood loss at the time of radical prostatectomy:
results from the SEARCH database. Prostate Cancer Prostatic Dis. Mar 2009. Epub
ahead of print.
121. Banez LL, Terris MK, Aranson WJ, Presti JC Jr, Kane CJ, Amling CL, Freedland
SJ. Race and time from diagnosis to radical prostatectomy: does equal access mean equal
timely access to the operating room? Cancer Epidemiology Biomarkers Prev. 18(4);
1208-12, Apr 2009.
122. Amling CL. Quality of life and satisfaction with prostate cancer treatment. Curr
Urol Rep.10(3):161-2, May 2009.
123 Colli JL, Amling CL. Chemoprevention of prostate cancer: what can be
recommended to patients? Curr Urol Rep 10(3):165-71, May 2009.

17
 124. Moreira DM, Jayachandran J, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ,
Amling CL, Stephenson AJ, Freedland SJ. Validation of a nomogram to predict disease
progression following salvage radiotherapy after radical prostatectomy: results from the
SEARCH database. BJU Int. May 2009. Epub ahead of print.
125. Moreira DM, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling
CL, Freedland SJ. Predictors of secondary treatment following biochemical recurrence
after radical prostatectomy: results from the Shared Equal Access Regional Cancer
Hospital database. BJU June 2009. Epub ahead of print.
126. Banez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC
Jr, Kane CJ, Amling CL, Moul J, Freedland SJ. Body mass index and prostatic specific
antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
J Urol June 2009. Epub ahead of print.
127. Teeter AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland
SJ. Does early prostate specific antigen doubling time (ePSADT) after radical
prostatectomy, calculated using PSA values from the first detectable until the first
recurrence value, correlate with standard PSADT? A report from the Shared Equal Access
Regional Cancer Hospital Database Group. BJU Int June 2009. Epub ahead of print.
128. Amling CL. Early results of the selenium and vitamin E prostate cancer prevention
study. Curr Urol Rep.10(4):242-3, July 2009.

INVITED PUBLICATIONS AND BOOK CHAPTERS

1. Lerner, S.E., Amling, C.L., Kaynan, A.M., Blute, M.L. and Zincke, H.: The role of salvage surgery in
radio-recurrent/resistant carcinoma of the prostate. AUA Update, Vol 28 (Lesson 8), 1999.
2. Riffenburgh RH, Amling CL: Use of early PSA velocity to predict eventual abnormal values in men at
risk for prostate cancer. Am J Urol Rev 1(6):256-262, 2003.
3. Amling CL: Use of a Competency-Based Computerized Resident Evaluation System for Urology
Training Programs, AUA News, Vol 9, Issue 2, 2004.
4. Ward JW, Amling CL, McKusick MA: The use of percutaneous transcatheter embolization in urology.
AUA Update, Vol 22 (Lesson 39 ), 2003.
5. Amling CL:  How the addition of hormones improves outcome: Hormone therapy and surgery.  Eur 
Urol Supplements 3(1):27­31, 2004.
6. Amling CL:  Letter of Response – Reaction to Body Mass Index, Family Urology, Vol 9, Issue 2, 
Summer 2004.
7. Amling CL:  Commentary on Does Obesity Affect Outcome in Prostate Cancer. Am J Urol Rev
2(7):323-325, 2004
8. Amling CL. Hormonal therapy: orchiectomy. In: Bostwick D, Crawford D, Higano C, Roach M, eds.
Prostate Cancer Book. American Cancer Society; Fall 2004 (In press)
9. Amling CL. Surgery: questions to ask your medical team about surgery. In: Bostwick D, Crawford D,
Higano C, Roach M, eds. Prostate Cancer Book. American Cancer Society; Fall 2004
10. Amling CL. Definition of failure recurrence after primary therapy – radical prostatectomy. In:
Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. Comprehensive Textbook of Genitourinary
Oncology, 3rd Edition. Philadelphia, PA; Lippincott, Williams & Wilkins
11. Amling CL. Relationship Between Obesity and Prostate and Renal Cancer – Journal of Alternative and
Complementary Medicine
12. Amling CL. Evidence­Based Use of Neoadjuvant and Adjuvant Hormonal Therapy with 
Radiotherapy and Radical Prostatectomy. AUA Postgraduate Course Handout, May 2005.

18
13. Amling CL. Biochemical Recurrence after Localized Treatment, Urologic Clinics of North America, 
Vol 33, No 2, 2006.
14. Amling CL.  Prostate­specific Antigen and Detection of Prostate Cancer:  What Have We Learned 
about What Should We Recommend for Screening?  In: Current Treatment Options in Oncology, 
7:337­345, Philadelphia (PA), Current Science, 2006.
15. Amling CL and Clayton DB.  Urologic Principles for the General Surgeon. In: General Surgery: 
Principles and International Practice, Northport (NY), Springer (In press).
16. Amling CL, section editor. Prostate Cancer. In: Current Prostate Reports, Vol 6, No 1, Philadelphia
(PA): Current Medicine, February 2008.

PUBLISHED ABSTRACTS

1. Amling, C.L., Kinney, R.D., Dodge, R.K. and Robertson, C.N.: Image analysis of DNA ploidy and
cell proliferation in prostate cancer: correlation to tumor volume, Invasiveness and Gleason grade.
J Urol 149 (supplement): 394A, 1993.
2. Amling, C.L., Perez, L.M., Russell, L.C., Seigler, H.F. and Weinerth, J.L.: Primary genitourinary
melanoma: Review of 37 cases. J Urol 149 (supplement): 497A, 1993.
3. Amling, C.L., Kerns, B.M., Tello, J.W., Layfield, L.J. and Robertson, C.N.: Image analysis of
DNA ploidy on touch imprint specimens from small core needle biopsies of the prostate. J Urol 149
(supplement): 394A, 1993.
4. Perez, L.M., Amling C.L., Thrasher, J.B., Newman, G.E., Joyner, R.E. and Anderson, E.E.:
Palliative urinary diversion for ureteral obstruction as a consequence of metastatic prostate cancer.
J Urol 149 (supplement): 429A, 1993.
5. Amling, C.L., Thrasher, J.B., Frazier, H.A., Robertson, J.E., Vollmer, R.T. and Paulson, D.F.:
Radical cystectomy for squamous cell carcinoma of the bladder. J Urol 151 (supplement): 451A,
1994.
6. Amling C.L., Thrasher, J.B., Frazier, H.A. and Paulson, D.F.: Radical cystoprostatectomy for
transitional cell carcinoma of the prostate. J Urol 153 (supplement): 393A, 1995.
7. Amling, C.L., O’Hara, S.M., Wiener, J.S. and King, L.R.: Renal ultrasound changes following
pyeloplasty in children with UPJ obstruction: Long term outcome in 47 renal units. Pediatrics,
October 1995.
8. Amling, C.L., Bergstralh, E.J., Blute, M.L. and Zincke, H.: Charlson comorbidity score and
clinical Gleason grade predict long-term survival in patients with prostate cancer undergoing
radical prostatectomy. J Urol 157 (supplement): 796, 1997.
9. Blute, M.L., Amling, C.L., Bergstralh, E.J., Zincke, H. and Bostwick, D.G.: Impact of site-specific
positive margins in organ-confined prostate cancer. J Urol 157 (supplement): 805, 1997.
10. Amling, C.L., Martin, S.K., Blute, M.L. and Zincke, H.: Contemporary morbidity of radical
retropubic prostatectomy for localized prostate cancer. J Urol 157 (supplement): 989, 1997.
11. Amling, C.L., Elliott, D.S., Slezak, J.M., Blute, M.L. and Zincke, H.: Should patients with very
high serum PSA levels (≥ 50 ng/ml) undergo radical prostatectomy? J Urol 157 (supplement):
1247, 1997.
12. Amling, C.L., Bergstralh, E.J., Martin, S.K., Slezak, J.K., Blute, M.L. and Zincke, H: Longterm
outcome following preoperative androgen deprivation therapy for clincal stage T3 prostate cancer.
J Urol 157 (supplement): 1297, 1997.
13. Amling, C.L., Martin, S.K., Slezak, J.K., Blute, M.L. and Zincke, H.: Salvage prostatectomy for
radiation refractory prostate cancer. J Urol 159 (supplement): 1296, 1998.
14. Amling, C.L., Bergstralh, E.J., Blute, M.L. and Zincke, H.: Factors predicting outcome following
radical prostatectomy for DNA aneuploid prostate cancer. J Urol 159 (supplement): 492, 1998.
15. Amling, C.L., Bergstralh, E.J., Blute, M.L. and Zincke, H.: Prostate cancer progression rates
19
 following radical prostatectomy for patients with seminal vesicle involvement. J Urol 159
(supplement): 493, 1998.
16. Blute, M.L., Amling, C.L., Bryant, S.C. and Zincke, H.: Management and outcome of bilateral
synchronous solid renal neoplasms. J Urol 159 (supplement): 565, 1998.
17. Kane, C.J., Amling, C.L., Johnstone, P.A., Pak, N., Foley, J.P. and Moul, J.W.: Limited value of
bone scintigraphy and computed tomography in assessing biochemical failure after radical
prostatectomy. J Urol 161 (supplement): 677, 1999.
18. Tarman, G.J., Kane, C.J., Moul, J.W., Thrasher, J.B., Foley, J.P., Riffenburgh, R.H. and Amling,
C.L.: The impact of socioeconomic status on clinical parameters of radical prostatectomy patients
in an equal access healthcare system. J Urol 161 (supplement): 1272, 1999.
19. Amling, C.L., Kane, C.J., Ward, J.F., Roberts, J.L., Lance, R.S., Friedrichs, P.A. and Moul, J.W.:
The impact of obesity on pathologic variables and surgical complications in patients nndergoing
radical prostatectomy for clinically localized prostate cancer. J Urol 163 (supplement): 254, 2000.
20. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J. and Zincke, H.: Long-term hazard of
progression after radical prostatectomy in patients with clinically localized prostate cancer:
Continued risk of biochemical failure after five years. J Urol 163 (supplement): 1496, 2000.
21. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J. and Zincke, H.: Defining biochemical
progression after radical prostatectomy: What is the most appropriate PSA cut-point? J Urol 163
(supplement): 1264, 2000.
22. Borboroglu, P.G., Sands, J.P., Roberts, J.L. and Amling, C.L.: Risk factors for vesicourethral
anastomotic stricture after radical prostatectomy. J Urol 163 (supplement): 1288, 2000.
23. Borboroglu, P.G., Groff, W.F., Powell, C.R. and Amling, C.L.: Location of postive sextant biopsy
does not correlate with sites of positive surgical margins in radical prostatectomy specimens. J Urol
163 (supplement): 1434, 2000.
24. Ward, J.F., Nowacki, M.R., Sands, J.P. and Amling, C.L.: Malignant cells in prostate washings
predicts biochemical progression after radical prostatectomy. J Urol 163 (supplement): 1431,
2000.
25. Knight, M.K., Amling, C.L., Karnes, J., King, B.F., Blute, M.L. and Segura, J.W.: Diagnosis and
treatment of prostate cancer in patients after rectal resection. J Urol 163 (supplement): 398, 2000.
26. Borboroglu, P.G., Amling, C.L., Monga, M. and Kane, C.J.: Ureteral stenting after distal
ureteroscopy for stones: A prospective randomized study assessing pain, outcomes and
complications. J Urol 163 (supplement): 1502, 2000.
27. Borboroglu, P.G., Sur, R.L., Roberts, J.L. and Amling, C.L.: Repeat biopsy strategy in patients
with atypical small acinar proliferation (ASAP) or high grade prostatic intraepithelial neoplasia
(HGPIN) on initial prostate needle biopsy. J Urol 165 (supplement): 402, 2001.
28. Johnstone, P.A.S., McFarland, J.T., Riffenburgh, R.H. and Amling, C.L.: The efficacy of digital
rectal examination in the followup of patients undergoing external beam radiotherapy for prostate
cancer. J Urol 165 (supplement): 1336, 2001.
29. Gray, C.L., Sears, S.T., Puckett, M.K., Kane, C.J., Ward, J.F. and Amling, C.L.: Prospective
comparison of computed tomography and intravenous pyelography in the initial evaluation of
asymptomatic microhematuria. J Urol 165 (supplement): 1604, 2001.
30. Johnstone, P.A., Kane, C., Sun, L., Wu, H., Moul, J. and Amling, C.L.: The effect of ethnicity on
biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation
therapy in an equal-access health care system. Radiology 221 (P): 224-225 (abstract 31), 2001.
31. Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Hui N, Sexton W,
Soderdahl D, Skaare VK, Moul J: Epidemiology of prostate cancer, its treatment and outcome:
Introduction of the Department of Defense Center for Prostate Disease Research (DOD-CPDR)
multicenter prostate cancer database with 307,931 records on 13,878 men. Eur Urol Supplements
1(1):74, 2002.
32. Moul, J.W., McLeod, D.G., Amling, C.L., Lance, R., et al: Assessment of biochemical disease
free survival (DFS) in patients with hormonal therapy (HT) started for PSA-only recurrence

20
 following radical prostatectomy. J Urol 167 (supplement): 699, 2002.
33. Sun, L., McLeod, D.G., Amling, C.L., Lance, R., et al: Who likely receives hormonal therapy
(HT) after PSA-only recurrence following radical prostatectomy? A retrospective analysis on 3790
cases from DOD CPDR National Database. J Urol 167 (supplement): 1194, 2002.
34. Amling, C.L. and Riffenburgh, R.H.: The use or early PSA velocity to predict eventual
development of abnormal PSA values: Potential use in the early identification of men at risk for
prostate cancer. J Urol 167 (supplement): 1288, 2002.
35. Sur, R.L., Borboroglu, P.G., Roberts, J.L. and Amling, C.L.: A randomized prospective
comparison of extensive transrectal prostate biopsy to standard biopsy for the diagnosis of prostate
cancer. J Urol 167 (supplement): 1317, 2002.
36. Smith, L.J., Hollis-Perry, K.M., Redden, T., Mondragon, R.M., Amling, C.L.: Does extensive
prostate biopsy more accurately predict cancer grade, stage and margin status at the time of radical
prostatectomy? J Urol 167 (supplement): 1322, 2002.
37. Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL: Improved
clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2
prostate cancer: Results from the SEARCH database. J Urol 169 (supplement) 295, 2003.
38. Freedland SJ, Presti JC, Terris MK, Aronson WJ, Kane CJ, Elashoff DA, Amling CL: Should a
positive surgical margin following radical prostatectomy be pathological stage T2 or T3?: Results
from the SEARCH database. J Urol 169 (supplement) 300, 2003.
39. Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L, Chung
A, Soderdahl D, Donahue T, Xao M, Chang J: Natural history of prostate cancer in 3605 CPDR
patients receiving radical prostatectomy and factors affecting post-treatment clinical metastatsis in
the PSA era. J Urol 169 (supplement) 398, 2003.
40. Wu H, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L,
Chung A, Soderdahl D, Donahue T, Banez L: An algorithm with preoperative variables to predict
PSA recurrence in prostate cancer patients receiving radical prostatectomy. J Urol 169
(supplement) 399, 2003.
41. Crain DS, Roberts JL, Amling CL: Practice patterns in vasectomy reversal: Results of a
questionnaire study among practicing urologists. J Urol (supplement) 409, 2003.
42. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC: Percent of
biopsy cores with cancer is a significant independent predictor of PSA failure after radical
prostatectomy: Results from the SEARCH database. J Urol 169 (supplement) 444, 2003.
43. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W,
Kusuda L, Chung A, Soderdahl D, Donahue T: Pretreatment total testosterone level predicts
pathologic stage among radical prostatectomy patients with localized prostate cancer. J Urol 169
(supplement) 456, 2003.
44. Wu H, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Kusuda L, Donahue T, Foley
J, Chung A, Sexton W, Soderdahl D: Watchful waiting and predicting factors for secondary
treatment in prostate cancer. J Urol 169 (supplement) 493, 2003.
45. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK.
Obesity is an independent predictor of biochemical failure following radical prostatectomy. J Urol
171 (supplement) 115, 2004.
46. Amling CL, Spencer CR, Roberts JL: Practice patterns in transrectal ultrasound guided prostate
biopsy: Results of a questionnaire survey of practicing urologists. J Urol 171 (supplement) 478,
2004.
47. Wu H, Moul JW, Sun L, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O’Reilly
KJ, Hernandez J, Chung A, Smith K. Prostate cancer mortality after radical prostatectomy or
radiation therapy in men with clinically localized prostate cancer. J Urol 171 (supplement) 118,
2004.
48. Chen Y, Moul JW, Sun L, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O’Reilly
KJ, Hernandez J, Chung A, Smith K. Comtemporary experience with hormone refractory prostate

21
 cancer (HRPC-Stage D3) in the PSA era: Report from the DOD CPDR national database. J Urol
171 (supplement) 118, 2004.
49. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men
have better biochemical outcomes following radical prostatectomy? J Urol 171 (supplement) 272,
2004.
50. Chung A, Sun L, Carter CA, Moul JW, Zhao X, McLeod DG, Amling CL, Donahue TF, Kusuda
L, Sexton WJ, O’Reilly KJ, Hernandez J, Smith K. Changing face of prostate cancer in the PSA
era: Results from the CPDR national database. J Urol 171 (supplement) 125, 2004.
51. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW,
DonahueTF, Foley JP, Chung AK, McLeod DG: Pathologic variables and recurrence rates as
related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Urol
171 (supplement) 116, 2004.
52. Sexton WJ, McDonough RC, Hernandez J, Sun L, Moul JW, Amling CL, Donahue TF, Kusuda L,
O’Reilly KJ, Chung A, Smith K. Prostate cancer in men less than or equal to 40 years of age
during the PSA era. J Urol 171 (supplement) 126, 2004.
53. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Men
with normal pre-operative serum PSA values have better biochemical outcomes following radical
prostatectomy. J Urol 171 (supplement) 332, 2004.
54. Amling CL, Williams SR, Lance R, McLeod DG, Kusuda L, Donahue T, Foley J, Sexton W,
Soderdahl DW, Sun L, Moul JW: Does obesity increase intraoperative and postoperative
complications in men undergoing radical prostatectomy? J Urol 171 (supplement) 215, 2004.
55. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of
prostate needle biopsy cores with cancer from the most involved side of the biopsy is a better
predictor of PSA recurrence following radical prostatectomy than the total percent of cores with
cancer. J Urol 171 (supplement) 274, 2004.
56. Amling CL, Sun L, Moul JW, Chen Y, McLeod DG, Donahue TF, Kusuda L, Sexton WJ, O’Reilly
KJ, Hernandez J, Chung A, Smith K. Pre and post-surgery factors affecting the outcomes of
patients with intermediate risk prostate cancer. J Urol 171 (supplement) 277, 2004.
57. Moul JW, Sun L, Amling CL, Fia Y, Chen Y, McLeod DG, Donahue TF, Kusuda L, Sexton WJ,
O’Reilly KJ, Hernandez J, Chung A, Smith K. How long can radical prostatectomy (RP) safely be
delayed? CPDR experience from 3324 cases. J Urol 171 (supplement) 312, 2004.
58. Langenstroer P, Poulton T, Kramer B, Cutting B, Amling CL, Lance RS, Thrasher JB. Multi-
institutional evaluation of depo-provera for the treatment of hot flashes associated with androgen
ablation for prostate cancer. J Urol 171 (supplement) 384, 2004.
59. Altamar HO, Kolkow, S, Amling CL: Incidental genitourinary abnormalities detected by CT
colonography in a large colorectal cancer screening population. J Urol 173 (supplement) 384,
2005.
60. Sarvis J, Crain D, Williams S, Amling CL: Randomized prospective comparison of IV conscious
sedation and lidocaine block for prostate biopsy. J Urol 173 (supplement) 384, 2005.
61. Freedland SJ, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr. , and Kane CJ.
Prostate size and risk of high-grade, advanced cancer, and biochemical progression following
radical prostatectomy. J Urol 173 (supplement) 384, 2005.
62. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, and Terris MK: Agent
Orange exposure and Risk of Advanced Disease and Biochemical Progression after Radical
Prostatectomy: Results from the SEARCH Database. J Urol 175 (supplement) 42, 2006.
63. Bastian PJ, Gonzalgo ML, Mangold LA, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC
Jr., Epstein JI, Partin AW, and Freedland SJ: Pathological and Biochemical Outcomes after
Radical Prostatectomy for Men with a Biopsy Gleason Score of 8 to 10. J Urol 175 (supplement)
215, 2006.
64. Scales CD Jr., Amling CL, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Freedland SJ:
Can Unilateral Prostate Cancer be Reliability Predicted based upon Biopsy Features? J Urol 175

22
 (supplement) 373, 2006.
65. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, and Terris MK: Obesity,
Serum PSA, and Prostate Size: Implications for Prostate Cancer. J Urol 175 (supplement) 487,
2006.
66. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson
WJ, Kane CJ, and Carroll PR: Multi-institutional validation of the UCSF Cancer of the Prostate
Risk Assessment (CAPRA) for prediction of recurrence following radical prostatectomy. J Urol
175 (supplement) 531, 2006.
67. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, and Presti JC Jr.: Upgrading and
Downgrading of Prostate Needle Biopsies: Risk Factors and Clinical Implications. J Urol 175
(supplement) 534, 2006.
68. Nelles JL, Freedland SJ, Presti JC Jr., Terris MK, Aronson WJ, Amling CL, and Kane CJ: Nerve
Sparing Does Not Increase the Risk of Biochemical Recurrence Results From the SEARCH
Database. J Urol 177 (supplement) 6, 2007.
69. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson IM, Aronson WJ,
Terris MK, Kane CJ, Presti JC Jr., Amling CL, and Freedland SL: Are the Partin Tables Accurate
for Africian-American Men in the United States? J Urol 177 (supplement) 111, 2007.
70. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr.: The
Optimal Timing, Cutoff and Method of Calculation of Preoperative PSA Velocity to Predict
Relapse After Prostatectomy: A Report from SEARCH. J Urol 177 (supplement) 128, 2007.
71. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr., and Freedland SJ:
African American Race, Risk of Biochemical Recurrence, and PSADT after Radical
Prostatectomy. J Urol 177 (supplement) 131, 2007.
72. Shah SR, Freedland SJ, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and Terris MK: Agent
Orange Exposure Among Black Men is a Stronger Predictor of PSA Recurrence and Rapid Post-
recurrence PSADT Than Among White Men. J Urol 177 (supplement) 153, 2007.
73. Freedland SJ, Hamilton RJ, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, and Kane CJ:
Obesity, Risk of Biochemical Recurrence, and PSADT After Radical Prostatectomy. J Urol 177
(supplement) 154, 2007.
74. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL,
and Freedland SJ: Significance of the Apical Margin in Radical Prostatectomy: Results from the
SEARCH Database. J Urol 177 (supplement) 159, 2007.
75. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr.,
and Freedland SJ: Is a Positive Bladder Neck Margin Truly a T4 Lesion in the PSA Era? J Urol
177 (supplement) 282, 2007.
76. Clayton DB, Colli JL, Seale JR, Stewart AF, Lin HY, and Amling CL: The Kinetics of Prostate
Specific Antigen Decline as a Predictor of Outcomes in Patients Receiving Androgen Deprivation
Therapy for Prostate Cancer. J Urol 177 (supplement) 337, 2007.
77. Banez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK,
Presti JC Jr., and Freedland SJ: Can Hemodilution Explain the Lower PSA Concentrations Among
Obese Men? J Urol 177 (supplement) 468, 2007.
78. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL,
Hammontree LN and Kolettis PN: Computed Tomographic Angiography for Renal Donor
Evaluation Leads to Higher Exclusion Rate. J Urol 177 (supplement) 565, 2007.
79. Strang AM, Lockhart ME, Burns JR, Amling CL, and Kolettis PN: Short Term Outcomes of
Living Donor Allograft Nephrolithiasis in Renal Transplant Donors and Recipients. J Urol 177
(supplement) 594, 2007.
80. Scales CD, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Krupski TL, and Freedland
SJ: Does Practice Reflect the Evidence? Lymph Node Dissection with Radical Prostatectomy:
Results from the SEARCH Database. J Urol 179 (supplement) 3, 2008.
81. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, and Freedland

23
 SJ: Small TRUS Volume Predicts Clinically Significant Gleason Score Upgrading After Radical
Prostatectomy: Results from the SEARCH Database. J Urol 179 (supplement) 51, 2008.
82. Teeter AE, Aronson WJ, Presti JC, Terris MK, Amling CL, Kane CJ, and Freedland SJ: Does
Early PSADT, Calculated Starting at the First Detectable PSA After Radical Prostatectomy (RP),
Correlate with Standard PSADT? A Report from the SEARC Database Group. J Urol 179
(supplement) 65, 2008.
83. Banez LL, Hamilton RJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and Freedland
SJ: Higher Cholesterol Increases the Risk of Biochemical Failure After Radical Prostatectomy:
Results from the SEARCH Database Group. J Urol 179 (supplement) 68, 2008.
84. Teeter AE, Banez LL, Aronson WJ, Presti JC, Terris MK, Amling CL, Kane CJ, and Freedland SJ:
What Are the Factors Associated with a Short PSA Doubling Time? A Report from the SEARCH
Database Group. J Urol 179 (supplement) 149, 2008.
85. Lin DW, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, and Freedland SJ: Outcome
Among Men with Patholigical Gleason SUM 8-10 Prostate Cancer at the Time of Radical
Prostatectomy: Results from the SEARCH Database. J Urol 179 (supplement) 151, 2008.
86. Jayachandran J, Banez LL, Levy DE, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ,
and Freedland SJ: Risk Stratification Among Men with Positive Surgical Margins or Extracapsular
Disease After Radical Prostatectomy: Results from the Shared Equal Access Regional Cancer
Hospital (SEARCH) Database. J Urol 179 (supplement) 251, 2008.
87. Kane CJ, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti JC, Amling CL,
and Freedland SJ: PSA Velocity (PSAV) to Cancer-Specific PSA (PSA(PCA)) Ratio Increases
with Higher Gleason Score: Results from the SEARCH Database. J Urol 179 (supplement) 601,
2008.
88. Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Sun L, Moul
JW, and Freedland SJ: Obesity as a Predictor of Adverse Outcome Across Black and White Race:
Results from the SEARCH and Duke Prostate Center Databases. J Urol 179 (supplement) 647,
2008.
89. Kane CJ, Terris MK, Aronson WJ, Presti JC, Amling CL, and Freedland SJ: Outcomes After
Radical Prostatectomy Among Men Who Are Candidates for Active Surveillance: Results from the
SEARCH Database. J Urol 179 (supplement) 651, 2008.
90. Klink JC, Banez LL, Powell IJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ:
T1C Disease in Black Men: A More Aggressive Disease? Results from the SEARCH Database. J
Urol 179 (supplement) 652, 2008.
91. Freedland SJ, Terris MK, Aronson WJ, Presti JC, Amling CL, and Kane CJ: Over the Last 15+
Years, the Percentage of Men Undergoing Radical Prostatectomy Who Are Candidates for Active
Surveillance Has Not Changed: Results From the SEARCH Database. J Urol 179 (supplement)
653, 2008.
92. Colli JL, Stands C, Martin B, and Amling CL: Urologist Population Density and PSA Screening
Practices Predict Prostate Cancer Mortality Rates in the United States. J Urol 179 (supplement)
687, 2008.
93. Freedland SJ, Moul JW, Sun L, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ,
Presti JC, Amling CL, and Kane CJ: Dynamic Screening Detects Prostate Cancer (PC) Earlier and
Would Lead to Improved Cancer Control: Results from the Duke Prostate Center and the
SEARCH Database. J Urol 179 (supplement) 688, 2008.
94. Clayton DB, Spencer CL, and Amling CL: Practice Patterns of Transrectal Ultrasound Guided
Prostate Biopsy: Results of a Questionaire Survey of Practicing Urologists. J Urol 179
(supplement) 712, 2008.
95. Banez LL, Sun L, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Moul JW, and
Freedland SJ: Is PSA a Poor Predictor of Adverse Pathology and Biochemical Failure Following
Radical Prostatectomy in Obese Men? J Urol 179 (supplement) 722, 2008.

24